Anika Therapeutics: Pay

Anika Therapeutics paid its 4 named executives $9.3M in total in FY2025 (Dec). CEO Stephen D. Griffin was paid $2.0M of that.

Pay$100 in the stock at the end of FY23 → $42
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Cheryl R. Blanchard, Ph.D.Executive Chair; Former President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Stephen D. GriffinPresident and Chief Executive Officer; Former EVP, Chief Financial Officer and Chief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
David B. Colleran EVPGeneral Counsel and Secretary
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Anne M. NunesFormer SVP, Chief Operations Officer
FY2024 (Dec)
FY2023 (Dec)
2 years
Ian W. McLeodSVP, Chief Accounting Officer and Treasurer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $6.8M. CEO pay of Anika Therapeutics for that year is not on file.

  1. 1Axogen
  2. 2Travere Therapeutics
  3. 3Mimedx Group
  4. 4Artivion
  5. 5Organogenesis Holdings
  6. 6Rigel Pharmaceuticals
  7. 7Vanda Pharmaceuticals
  8. 8Collegium Pharmaceutical
  9. 9Anika TherapeuticsNot disclosed
  10. 10Akebia TherapeuticsNot disclosed
  11. 11Atrion CorporationNot disclosed
  12. 12Avid Bioservices, Inc.Not disclosed
  13. 13BioventusNot disclosed
  14. 14Heron Therapeutics, Inc.Not disclosed
  15. 15Karyopharm Therapeutics, Inc.Not disclosed
  16. 16MacroGenics, Inc.Not disclosed
  17. 17SurModics, Inc.Not disclosed
  18. 18VericelNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.